Evidence map›Paper›PMID 34895154›Full record

ArticleBMC nephrology2021

Evaluation of recombinant human erythropoietin responsiveness by measuring erythrocyte creatine content in haemodialysis patients.

Shun Hasegawa, Seishi Nakamura, Tetsuro Sugiura, Yoshiaki Tsuka, Nobuyuki Takahashi, Koichiro Matsumura, Toshika Okumiya, Masato Baden, Ichiro Shiojima

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC nephrology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Shun HasegawaDepartment of Nephrology and Cardiology, Takarazuka Hospital, 2-1-2 Nogami, Takarazuka, Hyogo, 665-0022, Japan.
Seishi NakamuraDepartment of Nephrology and Cardiology, Takarazuka Hospital, 2-1-2 Nogami, Takarazuka, Hyogo, 665-0022, Japan. rintaro@hcc6.bai.ne.jp.
Tetsuro SugiuraThe Second Department of Internal Medicine, Kansai Medical University, Osaka, Japan.
Yoshiaki TsukaDepartment of Nephrology and Cardiology, Takarazuka Hospital, 2-1-2 Nogami, Takarazuka, Hyogo, 665-0022, Japan.
Nobuyuki TakahashiDepartment of Nephrology, Kansai Medical University Kori Hospital, Osaka, Japan.
Koichiro MatsumuraThe Second Department of Internal Medicine, Kansai Medical University, Osaka, Japan.
Toshika OkumiyaGraduate School of Health Sciences, Kumamoto University, Kumamoto, Japan.
Masato BadenDepartment of Nephrology and Cardiology, Takarazuka Hospital, 2-1-2 Nogami, Takarazuka, Hyogo, 665-0022, Japan.
Ichiro ShiojimaThe Second Department of Internal Medicine, Kansai Medical University, Osaka, Japan.
Kansai Medical University · JPTakarazuka City Hospital · JPKumamoto University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOne of the main causes of anaemia in patients with end-stage renal disease is relative deficiency in erythropoietin production. Eythropoiesis stimulating agent (ESA), a potent haematopoietic growth factor, is used to treat anaemia in haemodialysis patients. The effect of ESA is usually assessed by haematological indices such as red blood cell count, haemoglobin concentration and haematocrit, but erythrocyte indices do not provide information of the rapid change in erythropoietic activity. As erythrocyte creatine directly assess erythropoiesis, the aim of this study was to evaluate the effect of ESA in haemodialysis patients by measuring the erythrocyte creatine content.

methodsESA dose was fixed 3 months prior to the enrollment and was maintained throughout the entire study period. Erythrocyte creatine was measured with haematologic indices in 83 haemodialysis patients. Haemoglobin was also measured 3 months after.

resultsESA dose (152.4 ± 62.9 vs. 82.2 ± 45.5 units/kg/week, P = 0.0001) and erythrocyte creatine (2.07 ± 0.73 vs. 1.60 ± 0.41 μmol/gHb, p = 0.0003) were significantly higher in 27 patients with haemoglobin <10 g/dL compared to 56 patients with haemoglobin ≥10 g/dL. There was a fair correlation between ESA dose and the concentration of creatine in the erythrocytes (r = 0.55, P < 0.0001). Increase in haemoglobin (>0.1 g/dL) was observed in 37 patients, whereas haemoglobin did not increase in 46 patients. Erythrocyte creatine levels were significantly higher in those patients with an increase in haemoglobin compared to those without (2.04 ± 0.64 vs. 1.52 ± 0.39 μmol/gHb, p < 0.0001). When 8 variables (ESA dose, erythropoietin resistance index, C-reactive protein, intact parathyroid hormone, iron supplementation, presence of anaemia, erythrocyte creatine and reticulocyte) were used in the multivariate logistic analysis, erythrocyte creatine levels emerged as the most important variable associated with increase in haemoglobin (Chi-square = 6.19, P = 0.01).

conclusionErythrocyte creatine, a useful marker of erythropoietic capacity, is a reliable marker to estimate ameliorative effectiveness of ESA in haemodialysis patients.

Indexed as

Renal DialysisAgedAged, 80 and overAnemiaCreatineErythrocytesErythropoietinFemaleHumansMaleMiddle AgedRecombinant ProteinsTreatment OutcomeCreatineEPO protein, humanErythropoietinRecombinant ProteinsErythrocyte creatineErythropoiesisErythropoiesis stimulating agentHaemodialysisRenal anaemia

Identifiers

PMID34895154
PMCPMC8666014
OpenAlexW4200060775

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.